Daewoong Announces Additional Analysis of Phase 1 Clinical Trial for Fibrosis Treatment New Drug 'DWN12088'

Daewoong Pharmaceutical Headquarters Building Exterior (Photo by Daewoong Pharmaceutical)

[Asia Economy Reporter Chunhee Lee] Daewoong Pharmaceutical has conducted an additional analysis and announced the results of the Phase 1 clinical trial of the fibrosis treatment candidate substance 'DWN12088' in Australia.

Daewoong Pharmaceutical announced on the 6th that it presented an additional analysis of the results of the Phase 1 clinical trial of the fibrosis treatment candidate substance DWN12088 in Australia at the European Respiratory Society (ERS) Annual Congress held online from the 5th to the 8th (local time).

DWN12088 is a new drug candidate developed by Daewoong Pharmaceutical as the world's first fibrosis treatment that inhibits the PRS protein. It has a mechanism that reduces the action of the PRS protein, which affects collagen production, thereby suppressing the excessive production of collagen that causes fibrosis.

DWN12088 previously confirmed safety, pharmacokinetic characteristics, and potential as a treatment for idiopathic pulmonary fibrosis in the earlier Australian Phase 1 clinical trial. In addition, Daewoong Pharmaceutical further analyzed the Phase 1 clinical trial results to reduce mild gastrointestinal adverse reactions such as diarrhea and abdominal pain, which appeared similarly to existing treatments when taking the drug. As a result, it was confirmed that tolerance to discomfort such as adverse reactions increased or decreased depending on the dosing time of DWN12088.

Daewoong Pharmaceutical expects that if tolerance is improved in Phase 2 clinical trials through dosage adjustment and formulation development, the possibility of new drug success will increase. Based on these results, the company plans to apply for Phase 2 clinical trials in Korea and the United States next year.

Seungho Jeon, CEO of Daewoong Pharmaceutical, said, “DWN12088 is being developed for fibrosis treatment with a differentiated mechanism, and we are continuing research to further improve tolerance,” adding, “We will develop the world's first innovative new drug to treat fibrosis in various tissues such as the heart, liver, kidneys, and skin, as well as the lungs.”

This content was produced with the assistance of AI translation services.